HR Execs on the Move

Synoptics

www.synoptics.co.uk

 
Synoptics was formed in 1985 by three researchers from the University of Cambridge who had developed a `tool box` for the generation of image analysis applications. The business grew quickly with many major companies using Synoptics to help develop imaging solutions across a wide range of applications. With a growing knowledge of CCD camera technology, frame grabbing and image capture techniques the company was able to enhance its skill sets within digital imaging.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Katecho

Katecho is a Des Moines, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Q Macs

Q Macs is a Richardson, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medicom

Medicom is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Carter Dental Lab

Carter Dental Lab is a Stuttgart, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioSig

BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.